Corporate News
Corporate News archive
2023
2022
2021
Corporate News PDF Archive
2020 (Text messages)
2020
- 20200420_Biofrontera_2019_Earnings_Release_EN_final.pdf
- 20200417_Q1_2020_prelim_revenue_EN_final.pdf
- 20200409_YE_con_call_details_EN_final.pdf
- 20200320_Covid_19_measures_EN_final.pdf
- 20200310_label_extension_EU-EN_final.pdf
- 20200219_update_clinical_developments_EN_final.pdf
- 20200203_EMA_positive_opinion_EN_final.pdf
- 20200131_restructuring_and_Duenwald_EN_final.pdf
- 20200114_follow_up_results_periphery_EN_final.pdf
- 20200106_reorganisation_Inc_EN_final.pdf
2019
- 190711_PM HV 2019_EN_v2_final.pdf (235 KB)
- 190724_PM Ergebnis Erwerbsangebote_EN_v2_final.pdf (186 KB)
- 2019.03.25_BFRA corporate update_EN_v4_final.pdf (276 KB)
- 2019.03.27_PM_Aufsichtsrat_EN_v2_final.pdf (184 KB)
- 2019.04.02_Maruho Angebot Info_EN_v2_final.pdf (184 KB)
- 2019.04.15_Q1 2019 prelim revenue_EN_v3_final.pdf (230 KB)
- 2019.04.16_con call details_EN_v1_final.pdf (167 KB)
- 2019.04.16_Studienergebnisse sekundäre Endpunkte_EN_v3_final.pdf (235 KB)
- 2019.04.25_PM Einberufung HV_EN_v2_final.pdf (203 KB)
- 2019.04.29_2018 Earnings Release_EN_v8_final.pdf (234 KB)
- 2019.05.16_con call details_EN_v1_final.pdf (180 KB)
- 2019.05.29_Biofrontera 1Q19 Earnings Release_EN_v8_final.pdf (256 KB)
- 2019.06.04_Nominierung AR_EN_v1_final.pdf (180 KB)
- 2019.06.12_RJ and JMP Conference_EN_v1_final.pdf (180 KB)
- 2019.06.21_PM Angebot Maruho_EN_final.pdf (186 KB)
- 2019.07.08_HJ1 2019 prelim revenue_EN_v2_final.pdf (227 KB)
- 2019.08.05_PM_corporate update CLS integration_EN_v6_final.pdf (185 KB)
- 2019.08.14_con call details_EN_v1_final.pdf (179 KB)
- 2019.09.17_Antrag EMA_EN_v3_final.pdf (183 KB)
- 2019.09.17_Baader Investment Conference_EN_v1_final.pdf (176 KB)
- 2019.10.23_Fall Clinical_DE_v4_final.pdf (101 KB)
- 2019.11.06_con call details_EN_final.pdf (186 KB)
- 20190108_PM_upscaling batch size_EN_final.pdf (285 KB)
- 20190211_PM_Arzneimittel-Schutzrichtlinie_EN_final.pdf (130 KB)
- 20190225_PR_SteveAwards_EN_final.pdf (132 KB)
- 20190701_PM Angebot Balaton_EN.pdf (88 KB)
- 20190827_H1 2019 Earnings Release_EN_v3_final.pdf (208 KB)
- 20191122_conference participation_EN_v1_final.pdf (198 KB)
- 20191213_CCO BF Inc._EN_final.pdf (188 KB)
- 20191220_aoHV Ergebnis_EN_final.pdf (203 KB)
2018
- 20181227_PR_Dusa disctrict court_EN_final.pdf (402 KB)
- 20181213_PM_unabhängige Prüfung_EN_final.pdf (144 KB)
- 20181126_Conference Participation_EN.pdf (234 KB)
- 20181116_Q3 2018 Earnings Release_EN_final.pdf (288 KB)
- 20181105_PM_Q3 Con Call Datum_EN_final.pdf (233 KB)
- 20181015_ Dawson James 2018 Conference_EN_final.pdf (670 KB)
- 20181001_PM_Tageslicht CH_EN_final.pdf (665 KB)
- 20180926_PM_Patientenrekrutierung_EN_final.pdf (653 KB)
- 20180924_PM_Cantor Fitzgerald Healthcare Conference_EN_final.pdf (665 KB)
- 20180919_PM_Baader Investment Conference_EN_final.pdf (667 KB)
- 20180917_PM_Endless Summer Umsatz_EN_final.pdf (669 KB)
- 20180831_Biofrontera 2Q18 Earnings Release_EN_correction.pdf (730 KB)
- 20180831_ 2Q18 Earnings Release_EN.pdf (738 KB)
- 20180830_PM_HJConCallReminder_EN.pdf (668 KB)
- 20180816_PM_VA contract award_EN_final.pdf (671 KB)
- 20180815_PM_HJ Con Call Datum_EN_final.pdf (668 KB)
- 20180802_PM_Balaton Offer US_EN_final.pdf (667 KB)
- 20180730_PM_2nd joint opinion_DBB_EN.pdf (676 KB)
- 20180726_PM_Patientenrekrutierung_EN.pdf (127 KB)
- 20180713_AGM_EN.pdf (119 KB)
- 20180712_DUSA_PM_EN.pdf (117 KB)
- 20180710_PM_Biofrontera on Collaboration_EN.pdf (117 KB)
- 20180706_FreiwilligePrüfung_EN.pdf (150 KB)
- 20180705_PR_HJ1 results_EN.pdf (119 KB)
- 20180612_lawsuit_DB_EN.pdf (107 KB)
- 20180611_Jointopinion_DBBAG_EN.pdf (114 KB)
- 20180530_PM Balaton offer_EN.pdf (116 KB)
- 20180530_ 1stQEarningsRelease_EN.pdf (142 KB)
- 20180529_PRSalesforce_UK_EN.pdf (44 KB)
- 20180522_Telco_1Q_EN.pdf (40 KB)
- 20180430_PR2017Annualresult_EN.pdf (146 KB)
- 20180426 PR Balaton offer_EN.pdf (40 KB)
- 20180419_Telco_AR_EN.pdf (39 KB)
- 20180315_RückzahlungWSV_EN.pdf (59 KB)
- 20180315_BezugspreiseWSV_EN.pdf (45 KB)
- 20180228_PR_BCC_ReimbursementScotland_EN.pdf (41 KB)
- 20180216 PR Closing ADR_EN.pdf (47 KB)
- 20180122_2017_RevenuePre_EN.pdf (91 KB)
2017
- 01/30/2017 Biofrontera Launches New U.S. Website and increases sales force to Support Launch and Commercialization of Ameluz® (101 KB)
- 02/08/2017 Biofrontera adds body cream to belixos® dermo-cosmetics series (97 KB)
- 02/28/2017 Biofrontera to Present at Cowen and Company's 37th Annual Healthcare Conference (49 KB)
- 03/13/2017 Biofrontera Reports Detailed Phase III Results for Ameluz® in Combination with Daylight-PDT (111 KB)
- 04/03/2017 Notice of Annual Results 2016 (33 KB)
- 04/06/2017 Biofrontera Reports Full Year 2016 Financial Results (255 KB)
- 05/08/2017 Notice of first quarterly report of 2017 (32 KB)
- 05/19/2017 Biofrontera Reports First Quarter 2017 Financial Results (219 KB)
- 05/19/2017 EIB grants financing to Biofrontera (115 KB)
- 05/30/2017 Biofrontera to Present at the 2017 Marcum Microcap Conference (97 KB)
- 06/12/2017 Biofrontera Files Label Extension for Ameluz® in EU to include Treatment with Daylight-PDT for Actinic Keratosis (241 KB)
- 08/02/2017 Ameluz® launch for Actinic Keratosis in Israel (42 KB)
- 08/04/2017 Biofrontera Agrees with U.S. FDA on Ameluz® Development Plan to Treat Basal Cell Carcinoma (121 KB)
- 08/09/2017 Biofrontera strengthens its U.S. sales support services (417 KB)
- 08/21/2017 Advanced notice of conference calls on half-year report of 2017 (35 KB)
- 08/30/2017 Biofrontera to Present at the 19th Annual Rodman & Renshaw Global Investment Conference (112 KB)
- 08/31/2017 Biofrontera Grows Revenues and Improves Financial Position in First Half 2017 (112 KB)
- 09/28/2017 Biofrontera Strengthens U.S. Team with Appointment of Jeffrey Holm as Vice President of Marketing (38 KB)
- 10/09/2017 Biofrontera’s Ameluz® and BF-RhodoLED® Listed on the U.S. VA Federal Supply Schedule (38 KB)
- 10/16/2017 Biofrontera to Present at the McGuire Woods 9th Annual Pharmaceutical and Medical Device Conference (35 KB)
- 10/18/2017 Biofrontera achieves strong U.S. sales performance of Ameluz® in first year of commercialization (47 KB)
- 11/10/2017 CMS issues new reimbursement codes for Ameluz® and for Photodynamic Therapy (48 KB)
- 11/20/2017 Biofrontera Announces Conference Call to Discuss Third Quarter 2017 Financial Results (40 KB)
- 11/26/2017 Biofrontera Reports Financial Results for Third Quarter and First Nine Months of 2017 (133 KB)
- 12/04/2017 Biofrontera to Present at the 10th Annual LD Micro Main Event (278 KB)
- 12/19/2017 Biofrontera Files Investigational New Drug Application (272 KB)
2016
- 01/26/2016 FDA completes Biofrontera’s Ameluz® NDA mid-cycle review (151 KB)
- 02/11/2016 Data from pivotal Phase III studies with BF-200 ALA: First introduction to US dermatologists as a poster and two oral presentations at the 14th South Beach Symposium (199 KB)
- 03/04/2016 Biofrontera announces full results of Phase III clinical trial evaluating BF-200 ALA for treatment of basal cell carcinoma (BCC) (207 KB)
- 03/31/2016 Swiss compulsory health insurance reimburses Ameluz® for treatment of actinic keratosis (196 KB)
- 04/04/2016 Biofrontera Announces NDA Progress Update for BF-200 ALA (246 KB)
- 04/07/2016 Notice of Annual Results 2016 (97 KB)
- 04/13/2016 Israel Ministry of Health Approves Biofrontera’s Ameluz® for treatment of actinic keratosis (244 KB)
- 04/14/2016 Biofrontera Reports Full Year 2015 Financial Results (201 KB)
- 04/28/2016 Announcement of adjustment of the option price of warrants (252 KB)
- 05/11/2016 Biofrontera Announces U.S. FDA Approval of Ameluz® and Activating BF-RhodoLED® Device for Treatment of Actinic Keratosis (253 KB)
- 05/23/2016 Notice of quarterly report of 2016 (98 KB)
- 05/25/2016 Biofrontera Reports First Quarter 2016 Financial Results and Business Update (268 KB)
- 06/02/2016 Biofrontera Announces Appointment of Four New Supervisory Board Members (251 KB)
- 06/23/2016 Biofrontera Progresses with Expansion of U.S. Subsidiary with Key Personnel Hires (198 KB)
- 06/30/2016 Biofrontera Initiates Phase III Trial of Ameluz® in Combination with Daylight-PDT (301 KB)
- 07/08/2016 Biofrontera Expands belixos® Dermo-Cosmetics Product Line with belixos® To Go (292 KB)
- 07/25/2016 Biofrontera to Present at the Canaccord Genuity Annual Growth Conference (96 KB)
- 08/25/2016 Biofrontera Accelerates Production of BF-RhodoLED® Lamps to Prepare for U.S. Commercial Launch (41 KB)
- 08/25/2016 Notice of half-year report of 2016 (33 KB)
- 08/29/2016 Biofrontera to Present at the 18th Annual Rodman & Renshaw Global Investment Conference (33 KB)
- 08/30/2016 Biofrontera Reports Financial Results and Business Update for Second Quarter and First Half 2016 (90 KB)
- 09/16/2016 Biofrontera Receives Label Expansion for Ameluz® in Europe to Include Field Cancerization (179 KB)
- 09/19/2016 Biofrontera Completes Patient Recruitment of Phase III Trial of Ameluz® in Combination with Daylight-PDT (79 KB)
- 10/07/2016 Biofrontera to Present at the Dawson James Securities 2nd Annual Growth Stock Conference (106 KB)
- 10/18/2016 Biofrontera Initiates U.S. Commercial Launch of Ameluz® for Actinic Keratosis (208 KB)
- 10/20/2016 Biofrontera Announces 12-Month Follow-Up Results of Phase III Trial Evaluating Ameluz® for Basal Cell Carcinoma (114 KB)
- 07/28/2016 Biofrontera Receives Favourable CHMP Assessment for Field-Directed Therapy and Files BCC Application (54 KB)
- 11/24/2016 Notice of 3rd quarterly report 2016 (33 KB)
- 11/28/2016 Biofrontera Reports Financial Results and Business Update for Third Quarter and First Nine Months 2016 (90 KB)
- 11/28/2016 European Commission provides unlimited approval for Ameluz® (72 KB)
- 11/30/2016 Biofrontera to Present at the 9th Annual LD Micro Main Event (33 KB)
- 12/20/2016 European Medicines Agency recommends indication expansion of Ameluz® for treatment of basal cell carcinoma (BCC) (136 KB)
2015
- 01/22/2015 Biofrontera AG selects designated sponsor in Germany (85 KB)
- 01/26/2015 Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz® (100 KB)
- 03/24/2015 Biofrontera starts Sales and Marketing of Ameluz® in Spain (156 KB)
- 03/29/2015 Notice of Annual Results 2014 (85 KB)
- 04/08/2015 Biofrontera stabilizes shareholder structure (100 KB)
- 04/09/2015 Biofrontera significantly increases its turnover in Germany in 2014 (107 KB)
- 04/16/2015 Biofrontera starts with robust growth into the new year (110 KB)
- 04/19/2015 Biofrontera establishes subsidiary in the US (145 KB)
- 05/06/2015 Biofrontera delivers excellent results from the Phase III study for field therapy of actinic keratosis for publication (108 KB)
- 05/22/2015 Notice of First Quarter Results 2015 (75 KB)
- 05/29/2015 Biofrontera delivers strong performance for Q1 2015 (113 KB)
- 06/22/2015 Biofrontera completes final steps ahead of FDA New Drug Application in the USA (111 KB)
- 07/13/2015 Biofrontera submits New Drug Application for Ameluz® to FDA (169 KB)
- 07/16/2015 Biofrontera launches ‘Belixos® Protect’, a daily skincare product for sun-damaged skin (140 KB)
- 07/22/2015 Biofrontera appoints Christoph Dünwald as Chief Commercial Officer (111 KB)
- 08/07/2015 Biofrontera AG Notice of First Half Year Results 2015 (86 KB)
- 08/13/2015 Biofrontera progresses well in first half year 2015 (107 KB)
- 31/08/2015 Biofrontera - Result of Annual General Meeting (94 KB)
- 09/21/2015 Excellent long-term outcome with field treatment of actinic keratosis with Ameluz® (92 KB)
- 10/01/2015 FDA determines May 10, 2016 as PDUFA* date for Ameluz® (133 KB)
- 11/11/2015 Biofrontera's business operations on track (128 KB)
- 11/12/2015 Biofrontera AG Notice of Third Quarter Results 2015 (76 KB)
- 11/19/2015 Biofrontera reports final patient visit in phase III trial for basal cell carcinoma (78 KB)
- 11/20/2015 Q3 Results well on track (129 KB)
- 12/07/2015 Swissmedic grants marketing approval for Ameluz® in Switzerland (79 KB)
- 12/13/2015 FDA grants small business waiver (97 KB)
2014
- 02/21/2014 Belixos® - nature‘s best to nurture your skin! Social media campaign started02/21/2014 Belixos® - nature‘s best to nurture your skin! Social media campaign started (207 KB)
- 02/27/2014 Biofrontera expands the Belixos® cosmeceutical product series (190 KB)
- 03/26/2014 Biofrontera publishes financial report 2013 (217 KB)
- 05/19/2014 Biofrontera AG publishes 1st quarter 2014 interim report (218 KB)
- 07/02/2014 PDT with Ameluz® is the most efficacious treatment option for actinic keratosis (78 KB)
- 08/06/2014 First Ameluz® sales in Central Eastern European region (127 KB)
- 08/11/2014 Ameluz® has passed first stage in approval process in Israel (89 KB)
- 08/18/2014 Belixos® now available through Amazon in Germany and UK (123 KB)
- 08/21/2014 Pre-NDA meeting scheduled with FDA for the approval of Ameluz® and BF-RhodoLED® (133 KB)
- 08/29/2014 Half Year Results: Progress in business operations (256 KB)
- 11/11/2014 Biofrontera AG hosts conference call on 13 November 2014 to present results of the 3rd quarter 2014 (100 KB)
- 11/13/2014 Biofrontera publishes report on the third quarter of 2014 (113 KB)
- 11/25/2014 Further progress in international approval processes of Biofrontera’s Ameluz® (151 KB)
- 12/05/2014 Biofrontera launches new addition Belixos® Gel to its derma-cosmetic line (97 KB)
2013
- 01/08/2013 Biofrontera receives positive EMA opinion on extended storage conditions for Ameluz® (91 KB)
- 03/12/2013 Biofrontera explains corporate strategy and clinical development program in telephone conference (85 KB)
- 03/25/2013 Maschmeyer increases share holding in Biofrontera AG (79 KB)
- 04/11/ 2013 Biofrontera AG to host conference call on 15 April 2013 to present results of the fiscal year 2012 (140 KB)
- 04/15/2013 Biofrontera AG publishes financial results for 2012 (101 KB)
- 05/17/2013 Biofrontera publishes 1st quarter 2013 interim report (226 KB)
- 06/04/2013 Biofrontera AG appoints Thomas Schaffer as CFO (89 KB)
- 06/10/2013 Biofrontera AG with new Corporate Website (81 KB)
- 08/01/2013 Biofrontera AG appoints M.M.Warburg & CO as new Designated Sponsor (164 KB)
- 08/23/2013 Biofrontera AG reports half-year financial results for 2013 (79 KB)
- 09/06/2013 Biofrontera announces brokerage agreement and research coverage with finnCap (79 KB)
- 09/20/2013 Actinic keratosis, most efficiently treated by Ameluz®, recognized as occupational disease (169 KB)
- 10/14/2013 Patient recruitment started in phase III study for field-therapy of actinic keratosis (89 KB)
- 10/21/2013 Allergan launches Ameluz® in Spain (101 KB)
- 11/08/2013 Biofrontera publishes interim report for the 3rd quarter of 2013 (90 KB)
- 12/12/2013 All Wales Medicine Strategy Group recommends the use of Ameluz® (88 KB)